{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:54:10Z","timestamp":1781744050210,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aim<\/jats:title>\n                    <jats:p>Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) remains controversial regarding the impact of moderate alcohol consumption on disease progression and clinical outcomes. This systematic review aimed to evaluate the effects of moderate alcohol intake (up to 30\u00a0g\/day for men and 20\u00a0g\/day for women) on the development and progression of Steatotic Liver Disease (SLD), including outcomes such as histopathological progression, hepatocellular carcinoma (HCC), cardiovascular disease, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The review followed PRISMA guidelines and included longitudinal cohort studies identified through PubMed, Scopus, Web of Science, Embase, and LILACS. Nine studies were selected for qualitative analysis, and seven were included in the meta-analysis. Effect measures, Hazard Ratios (HR) and Odds Ratios (OR), were pooled using Cochrane RevMan, and study quality was assessed with the Newcastle\u2013Ottawa Scale. PROSPERO: CRD420261277466.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The meta-analysis showed no statistically significant association between moderate alcohol consumption and fibrosis progression (HR: 1.63 [95% CI: 0.96\u20132.77]; OR: 1.44 [95% CI: 0.56\u20133.72]). However, a statistically significant protective association was observed for all-cause mortality (HR: 0.73 [95% CI: 0.62\u20130.86]). High heterogeneity was noted across studies (I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200956.9\u201386.2%). Excessive alcohol consumption remained a strong risk factor for adverse outcomes, and the incidence of HCC significantly increased among patients with advanced fibrosis, even with light alcohol intake.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Even moderate alcohol consumption may contribute to the progression of severe hepatic outcomes in SLD. These findings support clinical recommendations for total abstinence, particularly in patients with established fibrosis, to prevent progression to cirrhosis and hepatocellular carcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-04814-5","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:06:16Z","timestamp":1777532776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Moderate alcohol consumption and clinical outcomes in MASLD: a systematic review and meta-analysis of longitudinal cohorts"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6762-1581","authenticated-orcid":false,"given":"Neilson Silveira","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7698-6919","authenticated-orcid":false,"given":"Helma Pinchemel","family":"Cotrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2406-137X","authenticated-orcid":false,"given":"Ant\u00f4nio Ricardo Cardia Ferraz","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"4814_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4814_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","volume":"78","author":"F \u00c5berg","year":"2023","unstructured":"\u00c5berg F, Byrne CD, Pirola CJ, M\u00e4nnist\u00f6 V, Sookoian S. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. J Hepatol. 2023;78:191\u2013206. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.030.","journal-title":"J Hepatol"},{"key":"4814_CR3","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"4814_CR4","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"key":"4814_CR5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/gutjnl-2013-305718","volume":"63","author":"S Sookoian","year":"2014","unstructured":"Sookoian S, Casta\u00f1o GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut. 2014;63:530\u20132. https:\/\/doi.org\/10.1136\/gutjnl-2013-305718.","journal-title":"Gut"},{"key":"4814_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/jrsm.1675","volume":"15","author":"A Halman","year":"2024","unstructured":"Halman A, Oshlack A. Catchii: Empowering literature review screening in healthcare. Res Synth Methods. 2024;15:157\u201365. https:\/\/doi.org\/10.1002\/jrsm.1675.","journal-title":"Res Synth Methods"},{"key":"4814_CR7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/hep.30864","volume":"71","author":"F \u00c5berg","year":"2020","unstructured":"\u00c5berg F, Puukka P, Salomaa V, M\u00e4nnist\u00f6 S, Lundqvist A, Valsta L, et al. Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts. Hepatology. 2020;71:835\u201348. https:\/\/doi.org\/10.1002\/hep.30864.","journal-title":"Hepatology"},{"key":"4814_CR8","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.cgh.2018.01.026","volume":"16","author":"V Ajmera","year":"2018","unstructured":"Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, et al. Among Patients with Nonalcoholic Fatty Liver Disease, Modest Alcohol Use is Associated with Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol. 2018;16:1511-1520.e5. https:\/\/doi.org\/10.1016\/j.cgh.2018.01.026.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4814_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000003","volume":"7","author":"J Blomdahl","year":"2023","unstructured":"Blomdahl J, Nasr P, Ekstedt M, Kechagias S. Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD. Hepatol Commun. 2023;7:e0003. https:\/\/doi.org\/10.1097\/HC9.0000000000000003.","journal-title":"Hepatol Commun"},{"key":"4814_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/hep.30170","volume":"69","author":"Y Chang","year":"2019","unstructured":"Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung H-S, et al. Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology. 2019;69:64\u201375. https:\/\/doi.org\/10.1002\/hep.30170.","journal-title":"Hepatology"},{"key":"4814_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/00365520802555991","volume":"44","author":"M Ekstedt","year":"2009","unstructured":"Ekstedt M, Franz\u00e9n LE, Holmqvist M, Bendtsen P, Mathiesen UL, Bodemar G, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2009;44:366\u201374. https:\/\/doi.org\/10.1080\/00365520802555991.","journal-title":"Scand J Gastroenterol"},{"key":"4814_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/hep.30226","volume":"70","author":"K Hajifathalian","year":"2019","unstructured":"Hajifathalian K, Sagvand BT, McCullough AJ. Effect of alcohol consumption on survival in non-alcoholic fatty liver disease: a national prospective cohort study. Hepatology. 2019;70:511\u201321. https:\/\/doi.org\/10.1002\/hep.30226.","journal-title":"Hepatology"},{"key":"4814_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/hep4.1828","volume":"6","author":"M Janjua","year":"2022","unstructured":"Janjua M, Knuiman M, Divitini M, McQuillan B, Olynyk JK, Jeffrey GP, et al. Alcohol Consumption and Cardiovascular Outcomes in Patients With Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Hepatol Commun. 2022;6:526\u201334. https:\/\/doi.org\/10.1002\/hep4.1828.","journal-title":"Hepatol Commun"},{"key":"4814_CR14","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3748\/wjg.v24.i13.1440","volume":"24","author":"T Kimura","year":"2018","unstructured":"Kimura T, Tanaka N, Fujimori N, Sugiura A, Yamazaki T, Joshita S, et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol. 2018;24:1440\u201350. https:\/\/doi.org\/10.3748\/wjg.v24.i13.1440.","journal-title":"World J Gastroenterol"},{"key":"4814_CR15","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.cgh.2018.11.033","volume":"17","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol. 2019;17:1625-1633.e1. https:\/\/doi.org\/10.1016\/j.cgh.2018.11.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4814_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"key":"4814_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc2191","volume":"7","author":"HK Seitz","year":"2007","unstructured":"Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007;7:599\u2013612. https:\/\/doi.org\/10.1038\/nrc2191.","journal-title":"Nat Rev Cancer"},{"key":"4814_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357. https:\/\/doi.org\/10.1002\/hep.29367.","journal-title":"Hepatology"},{"key":"4814_CR19","doi-asserted-by":"publisher","DOI":"10.1159\/000549355","author":"J Li","year":"2025","unstructured":"Li J, Liang Y-B, Wang Q-B, Luo W-L, Chen X-M, Lakang Y, et al. Rechallenge with Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Narrative Review. Liver Cancer. 2025. https:\/\/doi.org\/10.1159\/000549355.","journal-title":"Liver Cancer"},{"key":"4814_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1714314","volume":"17","author":"J Li","year":"2026","unstructured":"Li J, Liang Y-B, Chen X-M, Ou Z-Y, Wang Q-B, Luo W-L, et al. Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk. Front Immunol. 2026;17:1714314. https:\/\/doi.org\/10.3389\/fimmu.2026.1714314.","journal-title":"Front Immunol"},{"key":"4814_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.freeradbiomed.2007.11.004","volume":"44","author":"Y Lu","year":"2008","unstructured":"Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med. 2008;44:723\u201338. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2007.11.004.","journal-title":"Free Radic Biol Med"},{"key":"4814_CR22","doi-asserted-by":"publisher","unstructured":"Gao Y-N, Chen M-L, Li W-M, Liu Q, Jiao Y. Advancing the diagnosis and treatment of metabolic-associated steatotic liver disease: The transformative role of artificial intelligence. Artificial Intelligence in Gastroenterology. Baishideng Publishing Group Inc.; 2025;6. https:\/\/doi.org\/10.35712\/aig.v6.i1.107105.\u00a0 [Cited 2025 Aug 5].","DOI":"10.35712\/aig.v6.i1.107105"},{"key":"4814_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.alcohol.2014.08.003","volume":"48","author":"A Heberlein","year":"2014","unstructured":"Heberlein A, K\u00e4ser M, Lichtinghagen R, Rhein M, Lenz B, Kornhuber J, et al. TNF-\u03b1 and IL-6 serum levels: neurobiological markers of alcohol consumption in alcohol-dependent patients? Alcohol. 2014;48:671\u20136. https:\/\/doi.org\/10.1016\/j.alcohol.2014.08.003.","journal-title":"Alcohol"},{"key":"4814_CR24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/acer.12250","volume":"38","author":"AD Plunk","year":"2014","unstructured":"Plunk AD, Syed-Mohammed H, Cavazos-Rehg P, Bierut LJ, Grucza RA. Alcohol consumption, heavy drinking, and mortality: rethinking the j-shaped curve. Alcohol Clin Exp Res. 2014;38:471\u20138. https:\/\/doi.org\/10.1111\/acer.12250.","journal-title":"Alcohol Clin Exp Res"},{"key":"4814_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0182-6","volume":"12","author":"M Roerecke","year":"2014","unstructured":"Roerecke M, Rehm J. Alcohol consumption, drinking patterns, and ischemic heart disease: a narrative review of meta-analyses and a systematic review and meta-analysis of the impact of heavy drinking occasions on risk for moderate drinkers. BMC Med. 2014;12:182. https:\/\/doi.org\/10.1186\/s12916-014-0182-6.","journal-title":"BMC Med"},{"key":"4814_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/acer.13981","volume":"43","author":"P Sarich","year":"2019","unstructured":"Sarich P, Canfell K, Banks E, Paige E, Egger S, Joshy G, et al. A prospective study of health conditions related to alcohol consumption cessation among 97,852 drinkers aged 45 and over in Australia. Alcohol Clin Exp Res. 2019;43:710\u201321. https:\/\/doi.org\/10.1111\/acer.13981.","journal-title":"Alcohol Clin Exp Res"},{"key":"4814_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.15288\/jsad.2016.77.185","volume":"77","author":"T Stockwell","year":"2016","unstructured":"Stockwell T, Zhao J, Panwar S, Roemer A, Naimi T, Chikritzhs T. Do \u201cmoderate\u201d drinkers have reduced mortality risk? A systematic review and meta-analysis of alcohol consumption and all-cause mortality. J Stud Alcohol Drugs. 2016;77:185\u201398. https:\/\/doi.org\/10.15288\/jsad.2016.77.185.","journal-title":"J Stud Alcohol Drugs"},{"key":"4814_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/aje\/kws252","volume":"177","author":"R Loomba","year":"2013","unstructured":"Loomba R, Yang H-I, Su J, Brenner D, Barrett-Connor E, Iloeje U, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol. 2013;177:333\u201342. https:\/\/doi.org\/10.1093\/aje\/kws252.","journal-title":"Am J Epidemiol"},{"key":"4814_CR29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","volume":"70","author":"N Ganne-Carri\u00e9","year":"2019","unstructured":"Ganne-Carri\u00e9 N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 2019;70:284\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.008.","journal-title":"J Hepatol"},{"key":"4814_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1530-0277.2008.00828.x","volume":"33","author":"MA Collins","year":"2009","unstructured":"Collins MA, Neafsey EJ, Mukamal KJ, Gray MO, Parks DA, Das DK, et al. Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies. Alcohol Clin Exp Res. 2009;33:206\u201319. https:\/\/doi.org\/10.1111\/j.1530-0277.2008.00828.x.","journal-title":"Alcohol Clin Exp Res"},{"key":"4814_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.35946\/arcr.v37.2.01","volume":"37","author":"G Szabo","year":"2015","unstructured":"Szabo G, Saha B. Alcohol\u2019s effect on host defense. Alcohol Res. 2015;37:159\u201370. https:\/\/doi.org\/10.35946\/arcr.v37.2.01.","journal-title":"Alcohol Res"},{"key":"4814_CR32","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/add.13757","volume":"112","author":"J Rehm","year":"2017","unstructured":"Rehm J, Gmel GE, Gmel G, Hasan OSM, Imtiaz S, Popova S, et al. The relationship between different dimensions of alcohol use and the burden of disease-an update. Addiction. 2017;112:968\u20131001. https:\/\/doi.org\/10.1111\/add.13757.","journal-title":"Addiction"},{"key":"4814_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019."},{"key":"4814_CR34","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461\u20135. https:\/\/doi.org\/10.1038\/ng.257.","journal-title":"Nat Genet"},{"key":"4814_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","volume":"73","author":"QM Anstee","year":"2020","unstructured":"Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort\u2606. J Hepatol. 2020;73:505\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.003.","journal-title":"J Hepatol"},{"key":"4814_CR36","doi-asserted-by":"publisher","unstructured":"Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. Elsevier; 2020;5:245\u201366. https:\/\/doi.org\/10.1016\/S2468-1253(19)30349-8.","DOI":"10.1016\/S2468-1253(19)30349-8"},{"key":"4814_CR37","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jncc.2025.05.001","volume":"5","author":"Y Xu","year":"2025","unstructured":"Xu Y, Xia C, Wang J, Wu Y, Chen W. Divergent trends in the burden of esophageal, gastric, and liver cancers in China. J Natl Cancer Cent. 2025;5:306\u201312. https:\/\/doi.org\/10.1016\/j.jncc.2025.05.001.","journal-title":"J Natl Cancer Cent"},{"key":"4814_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(02)07451-2","volume":"359","author":"DA Grimes","year":"2002","unstructured":"Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet. 2002;359:248\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(02)07451-2.","journal-title":"Lancet"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04814-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04814-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04814-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:20:25Z","timestamp":1781742025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04814-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4814"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04814-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review and meta-analysis of previously published longitudinal cohort studies and did not involve direct interaction with human participants or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not contain any individual person\u2019s data in any form (including individual details, images, or videos).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"368"}}